Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements are consistent with the label’s skeletal muscle warning (rare rhabdomyolysis, risk increased with certain interacting drugs) and include kidney injury as part of reported rhabdomyolysis. However, the specific interaction with 'potassium salt substitutes' is not supported by the provided label excerpts, and multiple additional claims extend beyond what is explicitly stated (e.g., potassium level changes/toxicity, relative likelihood, and general safety for most people).
Category Scores
Accurate Statements
Muscle damage (rhabdomyolysis) is a rare but serious condition that can occur with Lipitor.
5.1: 'Rare cases of rhabdomyolysis with acute renal failure... have been reported with LIPITOR.'
Rhabdomyolysis can lead to kidney damage.
5.1: 'rhabdomyolysis with acute renal failure secondary to myoglobinuria'.
Lipitor (atorvastatin) can increase the risk of muscle damage when taken with certain medications.
5.1: 'concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors… increases the risk of myopathy/rhabdomyolysis.'
Taking Lipitor with potassium salt substitutes can increase the risk of muscle damage.
Unsupported for potassium salt substitutes specifically (see unsupported/omission). Generic interaction with 'certain drugs' aligns with 5.1/7.
Unsupported Statements
Lipitor (atorvastatin) can increase the risk of muscle damage when taken with certain medications, including potassium salt substitutes.
The provided label excerpts list specific interacting drugs/classes (e.g., cyclosporine, strong CYP3A4 inhibitors, fibric acid derivatives, niacin) but do not mention 'potassium salt substitutes'.
Rhabdomyolysis is a rare but serious condition that can occur when Lipitor interacts with potassium salt substitutes.
Label excerpts do not mention potassium salt substitutes as a co-administered agent.
Rhabdomyolysis can lead to muscle pain.
The provided excerpts do not state muscle pain as a consequence of rhabdomyolysis.
Rhabdomyolysis can lead to muscle weakness.
The provided excerpts do not state muscle weakness as a consequence of rhabdomyolysis.
Taking Lipitor with potassium salt substitutes can increase the levels of potassium in the blood.
No provided label excerpt states that atorvastatin increases serum potassium or that potassium salt substitutes affect potassium in this context.
Excessive potassium levels can be toxic.
No provided label excerpt includes potassium-toxicity statements.
Patients taking atorvastatin (Lipitor) with potassium salt substitutes were more likely to experience muscle damage and other adverse effects.
No provided label excerpt includes data or comparative likelihood involving potassium salt substitutes.
Lipitor and potassium salt substitutes may be safe for most people.
No provided label excerpt addresses safety of this specific combination or uses a 'safe for most people' framing.
Monitoring potassium levels regularly helps ensure potassium remains within a safe range.
No provided label excerpt recommends potassium level monitoring for atorvastatin or for use with potassium salt substitutes.
Avoiding potassium salt substitutes in excess can decrease the risk of muscle damage.
No provided label excerpt provides guidance about potassium salt substitutes or dose-related avoidance for reducing muscle damage.
Contradictions
Important Omissions
The label excerpts specifically support muscle risk with certain interacting drugs (e.g., cyclosporine, strong CYP3A4 inhibitors, fibric acid derivatives/niacin). The AI claims focus on potassium salt substitutes without naming the label-supported interacting drugs/classes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because the interaction is attributed to 'potassium salt substitutes'—not supported by the provided label excerpts—the guidance could misdirect attention away from label-supported interacting drugs/classes that increase myopathy/rhabdomyolysis risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Key safety interaction claims are tied to 'potassium salt substitutes' and potassium-level effects that are not present in the provided FDA label excerpts.
Suggested Improvement
Restrict interaction-related risk statements to the specific agents/classes supported in the provided label (e.g., cyclosporine and strong CYP3A4 inhibitors; fibric acid derivatives or lipid-modifying doses of niacin) and avoid claims about potassium salt substitutes, potassium blood levels, potassium toxicity, potassium monitoring, or 'safe for most people' without label support.